Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EMISNYSE:SENS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/ASENSSenseonics$0.74+6.8%$0.65$0.25▼$1.40$482.03M1.056.35 million shs5.33 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%SENSSenseonics+4.55%-7.35%+24.23%-24.84%+37.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ASENSSenseonics2.2954 of 5 stars3.80.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMISEmisphere Technologies 0.00N/AN/AN/ASENSSenseonics 3.50Strong Buy$2.00171.44% UpsideCurrent Analyst Ratings BreakdownLatest SENS, IQAI, DVRG, and EMIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$2.004/9/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/5/2025SENSSenseonicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.00 ➝ $2.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/ASENSSenseonics$22.47M21.45N/AN/A$0.07 per share10.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ASENSSenseonics-$60.39M-$0.12N/AN/AN/A-362.30%-842.25%-67.99%N/ALatest SENS, IQAI, DVRG, and EMIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024SENSSenseonics-$0.03-$0.12-$0.09N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMISEmisphere TechnologiesN/AN/AN/AN/AN/ASENSSenseonicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMISEmisphere TechnologiesN/AN/AN/ASENSSenseonics59.172.472.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMISEmisphere TechnologiesN/ASENSSenseonics12.36%Insider OwnershipCompanyInsider OwnershipEMISEmisphere Technologies72.90%SENSSenseonics4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMISEmisphere Technologies6N/AN/ANot OptionableSENSSenseonics90654.22 million573.90 millionN/ASENS, IQAI, DVRG, and EMIS HeadlinesRecent News About These CompaniesSenseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call TranscriptMay 8 at 8:23 PM | seekingalpha.comSenseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue EstimatesMay 8 at 8:05 PM | zacks.comRenaissance Technologies LLC Makes New Investment in Senseonics Holdings, Inc. (NYSE:SENS)May 4, 2025 | marketbeat.comSenseonics (NYSE:SENS) Trading Up 6.3% - Here's What HappenedMay 1, 2025 | marketbeat.comSequel Med Tech and Senseonics Partner to Launch twiist™ AID System Compatible with Eversense® 365 CGMApril 30, 2025 | nasdaq.comSenseonics, Sequel partner to use 1-year CGM in automated insulin dosing systemApril 30, 2025 | medtechdive.comFirst Light Asset Management LLC Invests $3.37 Million in Senseonics Holdings, Inc. (NYSE:SENS)April 30, 2025 | marketbeat.comSequel Med Tech, Senseonics to integrate year-long CGM into automated insulin delivery systemApril 29, 2025 | drugdeliverybusiness.comSequel Med Tech to link Senseonics’ 365-day CGM with upcoming twiist insulin pumpApril 29, 2025 | fiercebiotech.comSequel strikes deal with Senseonics for one-year CGM systemApril 29, 2025 | msn.comSenseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern TimeApril 29, 2025 | globenewswire.comSequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)April 29, 2025 | globenewswire.comSequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)April 29, 2025 | globenewswire.comGeode Capital Management LLC Purchases 566,704 Shares of Senseonics Holdings, Inc. (NYSE:SENS)April 29, 2025 | marketbeat.comWhy Senseonics Holdings, Inc.’s (SENS) Stock Is Up 12.13%April 23, 2025 | aaii.comIs Senseonics Holdings (SENS) the Best Penny Stock to Invest in Under $1?April 16, 2025 | insidermonkey.comSenseonics (NYSE:SENS) Raised to Strong-Buy at MizuhoApril 13, 2025 | marketbeat.comMizuho Initiates Coverage of Senseonics Holdings (SENS) with Outperform RecommendationApril 10, 2025 | msn.comSenseonics initiated with an Outperform at MizuhoApril 10, 2025 | markets.businessinsider.comSenseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?March 6, 2025 | zacks.comSenseonics (NYSE: SENS) Sees 56% Growth in Patient Base Following...March 5, 2025 | kalkinemedia.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumTesla Earnings Miss, But Musk Refocuses and Bulls ReactBy Sam Quirke | April 23, 2025View Tesla Earnings Miss, But Musk Refocuses and Bulls ReactHidden Gems: 3 Quiet Stocks With Loud PotentialBy Nathan Reiff | April 23, 2025View Hidden Gems: 3 Quiet Stocks With Loud PotentialSENS, IQAI, DVRG, and EMIS Company DescriptionsEmisphere Technologies OTCMKTS:EMIS$7.81 0.00 (0.00%) As of 12/9/2020Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Senseonics NYSE:SENS$0.74 +0.05 (+6.78%) Closing price 04:00 PM EasternExtended Trading$0.69 -0.05 (-6.89%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
